Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder
Clicks: 278
ID: 112180
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
278 views
55 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #14 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Growing evidence supports the treatment of MDD through modulation of dysregulated glutamate neurotransmission. This study assessed the putative antidepressant and precognitive effects of decoglurant, a metabotropic glutamate receptor type 2/3 antagonist.
| Reference Key |
umbricht2020therandomized,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Daniel Umbricht;Markus Niggli;Patricia Sanwald-Ducray;Dennis Deptula;Rema Moore;Waltraud Grünbauer;Lauren Boak;Paulo Fontoura; |
| Journal | the journal of clinical psychiatry |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.